Eli Lilly has announced a significant acquisition, agreeing to pay up to $7.8 billion for Centessa Pharmaceuticals and its promising experimental drug targeting excessive daytime sleepiness. This move positions Lilly to enhance its neuroscience portfolio, particularly in treating narcolepsy and potentially other neurological conditions linked to drowsiness, such as Alzheimer’s and depression. The deal includes an upfront payment of $6.3 billion, reflecting a 38% premium on Centessa’s recent stock price, with additional payments contingent on FDA approval of Centessa’s drugs.
This acquisition is noteworthy as it taps into the lucrative market for orexin agonists, which could reach $15 billion to $20 billion if a quarter of patients seek treatment. Lilly’s stock rose about 3% following the announcement, while Centessa’s surged 45%, reflecting investor optimism about the deal’s potential.
For market professionals, this acquisition underscores Lilly’s strategy to leverage profits from its successful obesity and diabetes drugs to expand its therapeutic offerings, signaling a robust commitment to growth in the neuroscience sector.
Source: cnbc.com